• Oncopeptides' November 5 third-quarter 2026 earnings call featured CEO Sofia Heigis and CFO Henrik Bergentoft.
• Quarterly net sales rose 41% year over year to SEK 28.5 million, despite summer-related weakness.
• Management maintained its target for positive commercial cash flow during 2027; glioblastoma development remains separately funded.
• Expected fourth-quarter European Commission clearance for third-line Pepaxti could double the addressable patient population and average treatment cycles per patient.
• Initial glioblastoma data confirmed human blood-brain barrier penetration; October's approximately SEK 100 million directed share issue will fund further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.